(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
@ $54.86
Issued: 19 Apr 2024 @ 15:19
Return: 0.35%
Previous signal: Apr 19 - 14:44
Previous signal:
Return: 0.82 %
Live Chart Being Loaded With Signals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform...
Stats | |
---|---|
Today's Volume | 1.76M |
Average Volume | 1.78M |
Market Cap | 4.67B |
EPS | $0 ( 2024-02-20 ) |
Next earnings date | ( $-1.630 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -28.38 |
ATR14 | $3.21 (5.84%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Kulkarni Samarth | Buy | 19 582 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 18 378 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 1 204 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 19 582 | Stock Option (Right to Buy) |
2024-03-20 | Kasinger James R. | Buy | 33 333 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
63.60 |
Last 100 transactions |
Buy: 2 415 277 | Sell: 542 570 |
Volume Correlation
CRISPR Therapeutics AG Correlation
10 Most Positive Correlations | |
---|---|
TGTX | 0.924 |
VYNE | 0.917 |
TRKA | 0.913 |
LIXT | 0.906 |
XLRN | 0.898 |
GNLN | 0.897 |
ZGNX | 0.895 |
LITM | 0.893 |
KALV | 0.89 |
APTO | 0.886 |
10 Most Negative Correlations | |
---|---|
CFV | -0.899 |
SITM | -0.896 |
AMRB | -0.896 |
MTSI | -0.885 |
EVBG | -0.883 |
ASRVP | -0.881 |
GMII | -0.88 |
PSCC | -0.88 |
MMAC | -0.879 |
PEBK | -0.872 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CRISPR Therapeutics AG Correlation - Currency/Commodity
CRISPR Therapeutics AG Financials
Annual | 2023 |
Revenue: | $370.00M |
Gross Profit: | $239.75M (64.80 %) |
EPS: | $-1.940 |
Q4 | 2023 |
Revenue: | $200.00M |
Gross Profit: | $180.00M (90.00 %) |
EPS: | $1.120 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-23.42M (0.00 %) |
EPS: | $-1.410 |
Q2 | 2023 |
Revenue: | $70.00M |
Gross Profit: | $25.36M (36.23 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators